Table 3.
Follow-up data.
| Patients (n=712) | |
|---|---|
| In-hospital adverse events | |
| - Death | 4 (0.6) |
| - Peri-procedural MI (in semi-elective group) | 10/440 (2.2) |
| - Cerebrovascular accident | 1 (0.1) |
| - Target lesion revascularisation | 1 (0.1) |
| - Access site complications | 8 (1.1) |
| Cumulative 30-day adverse events | |
| - Death | 4 (0.6) |
| - Myocardial infarction | 14 (2.0) |
| - Cerebrovascular accident | 1 (0.1) |
| - Target lesion revascularisation | 6 (0.8) |
| - Target vessel revascularisation | 6 (0.8) |
| - Definite early stent thrombosis | 4 (0.6) |
| - Probable early stent thrombosis | 1 (0.1) |
| Cumulative 12-month adverse events | |
| - Death | 17 (2.4) |
| - Myocardial infarction | 20 (2.8) |
| - Cerebrovascular accident | 1 (0.1) |
| - Target lesion revascularisation | 19 (2.6) |
| - Target vessel revascularisation | 29 (4.1) |
| - Major adverse cardiac events | 59 (8.3) |
| - Definite early and late stent thrombosis | 7 (1.0) |
| - Probable early and late stent thrombosis | 4 (0.6) |
| - Possible stent thrombosis | 4 (0.6) |
Values are presented as numbers (%).